二甲双胍与不同种族/族裔群体前列腺癌风险:一项基于人群的队列研究
该研究利用行政数据库识别1994至2012年间50岁及以上糖尿病男性,采用时间依赖变量定义二甲双胍暴露并按累积剂量三分位分层,通过姓氏算法区分华裔与非华裔,多变量Cox回归估计前列腺癌风险。队列共80001人,平均年龄64岁,中位随访9年。结果显示二甲双胍与前列腺癌风险在两种族/族裔中均无明确关联,华裔各年龄组使用者与非使用者风险相似,非华裔仅50-59岁组风险降低(aHR 0.86,95%CI 0.74-1.00),但按三分位分层后仅部分亚组有关联。
要点
- 队列共80001名50岁及以上糖尿病男性,平均年龄64岁,中位随访9年。
- 华裔二甲双胍使用者各年龄组前列腺癌风险与非使用者相似。
- 非华裔50-59岁使用者风险降低(aHR 0.86,95%CI 0.74-1.00),60-69岁及≥70岁组无此关联。
核心结论
- 在糖尿病男性中,二甲双胍与前列腺癌风险在两种族/族裔中均无明确关联。
- 研究结果提示二甲双胍与前列腺癌的关系在种族/族裔间具有一致性。
研究设计与样本
- 基于行政数据库的人群队列研究,纳入1994至2012年间50岁及以上糖尿病男性共80001人。
- 二甲双胍暴露定义为时间依赖变量,先分为任何使用,再按累积剂量三分位分层。
- 采用姓氏算法识别个体为华裔或非华裔,多变量Cox回归估计前列腺癌风险。
主要发现
- 队列平均年龄64岁,中位随访9年。
- 华裔二甲双胍使用者年龄50-59岁、60-69岁及≥70岁的前列腺癌风险与非使用者相似。
- 非华裔使用者年龄50-59岁风险降低(aHR 0.86,95%CI 0.74-1.00),年龄60-69岁及≥70岁未降低。
- 按三分位分层后,非华裔50-59岁男性第一分位aHR 0.68(95%CI 0.55-0.84)、第二分位aHR 0.75(95%CI 0.61-0.92)、第三分位aHR 0.79(95%CI 0.64-0.96);非华裔60-69岁男性第一分位aHR 0.81(95%CI 0.68-0.95);其他分层均无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men with diabetes may have a lower risk of prostate cancer than men without diabetes which may be altered by metformin use or race/ethnicity. METHODS: Using administrative databases, from 1994 to 2012, adult (age⩾50 years) men with diabetes were identified. Metformin exposure was defined as a time-dependent variable, stratified first into any use, and into tertiles of cumulative dose. Surname algorithms identified individuals as Chinese or non-Chinese. Multivariable Cox regression estimated the risk of prostate cancer. RESULTS: The cohort of 80 001 had a mean age of 64 years and median follow-up of 9 years. Chinese users of metformin aged 50-59, 60-69 and ⩾70 had similar risks of prostate cancer as non-users. Non-Chinese users aged 50-59 (adjusted hazards ratio (aHR): 0.86, 0.74 to 1.00) had a decreased risk whereas men aged 60-69 and ⩾70 did not. However, when metformin exposure was stratified into tertiles, there was no association in any strata except non-Chinese men aged 50-59 in the first (aHR: 0.68, 95% confidence interval (CI): 0.55, 0.84), second (aHR: 0.75, 95% CI: 0.61, 0.92) and third (aHR: 0.79, 95% CI: 0.64, 0.96) tertiles of metformin exposure and non-Chinese men aged 60-69 in the first (aHR: 0.81, 95% CI: 0.68, 0.95) tertiles of metformin exposure. CONCLUSIONS: There was no clear association between metformin and risk of prostate cancer in men with diabetes in either race/ethnicity. Our findings suggest a consistent relationship between metformin and prostate cancer across race/ethnicity.
引用
- Chen CB, Eurich DT, Majumdar SR, et al. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study. Prostate Cancer Prostatic Dis. 2017. PMID: 28071672. doi:10.1038/pcan.2016.65
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。